Clinical

Dataset Information

0

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

ABSTRACT: Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors

DISEASE(S): Carcinoma,Cervical Cancer,Melanoma,Colorectal Cancer,Non Small Cell Lung Cancer,Mesothelioma,Pancreatic Cancer,Bladder Urothelial Cancer,Breast Cancer,Ovarian Cancer,Squamous Cell Carcinoma Of Head And Neck,Endocervical Cancer,Gastric Cancer,Esophageal Cancer,Carcinoma, Renal Cell,Prostate Cancer,Renal Cell Carcinoma,Cholangiocarcinoma

PROVIDER: 2717427 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Clinical Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
| 2402815 | ecrin-mdr-crc
Transcriptomics Expression of Pembrolizumab-treated tumors
2023-10-01 | E-MTAB-8288 | biostudies-arrayexpress
Clinical A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
| 2297842 | ecrin-mdr-crc
Clinical Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
| 2379568 | ecrin-mdr-crc
Genomics Advanced Genetic and Molecular Analysis of Solid Tumors
| PRJNA615692 | ENA
Genomics Advanced Genetic and Molecular Analysis of Solid Tumors
| PRJNA615693 | ENA
Clinical KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
| 91122 | ecrin-mdr-crc
Transcriptomics Paired tumour biopsy gene expression data from patients with solid tumours, before and after combination treatment.
2024-10-23 | GSE233860 | GEO
Genomics Discovery of a long half-life AURKA inhibitor to treat MYC-amplified solid tumors as a monotherapy and in combination with everolimus
| PRJNA1011872 | ENA
Genomics Clinical Implication of RAF1 aberrations in advanced solid tumors using next generation sequencing: a pan-tumor analysis
| PRJEB70258 | ENA